VELO providing resources, mentors, community and funding for those who want to pursue their side hustle, passion project, or dream business
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of cytisinicline, a process for their preparation, and their use in the prevention or treatment of CNS and addictive disorders.
Study will allow The Lundquist Institute to determine the multi-generational risks of developing asthma from vaping while pregnant
LungcastTM will feature conversations with researchers, physicians, patients and advocates about hot topics in lung health
Easy Access to Tobacco, Availability of Kid-Friendly Flavored Products Increase Risk of Youth Nicotine Addiction
New estimates from a web-based tool that tracks tobacco use created by the Yale School of Public Health show that the recent federal law raising the age of legal tobacco purchase to 21 could save over 100,000 lives over the rest of this century.
Collaboration broadens company’s portfolio of smoke-free products for those adults who would otherwise continue to smoke
Tobacco companies will compensate retailers for data through pricing discounts and consumer rebates
FDA applications are a first for VELO's dissolvable nicotine lozenges
Offers Opportunity to learn more about VELO's portfolio of modern oral products